Judge approves $200 million settlement in 2012 meningitis outbreak A Federal bankruptcy judge approved a $200 million settlement with the now-closed New England Compounding Center pharmacy following a 2012 fungal meningitis outbreak that killed 64 people and sickened more than 750 others across 20 states as a result of tainted drugs produced by the pharmacy. The settlement will be distributed among the victims and 14 former employees of the compounding center
Multiple sclerosis: Scientists identify cause of movement, balance problems New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty 'brake' within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis.
Cancer drugs may hold key to treating Down syndrome and other brain disorders A class of FDA-approved cancer drugs may be able to prevent problems with brain cell development associated with disorders including Down syndrome and Fragile X syndrome.
'Redesigned' antibodies may control HIV With the help of a computer program called “Rosetta,” researchers have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
Potential new drug target for the treatment of rheumatoid arthritis A novel drug target for the treatment of rheumatoid arthritis has been identified, which focuses on the cells that are directly responsible for the cartilage damage in affected joints. Rheumatoid arthritis, an autoimmune disease that leads to stiff, deformed joints and often crippling pain. The immune system's attack on the body's own tissue leads to chronic, painful inflammation in the affected joints.